Adocia-Analyse Department
In France, more than 3.5 million people live with diabetes. Eve-Marie, a person with type 1 diabetes, dreams of an insulin delivery system that could automatically manage her blood glucose. Part of the answer to that hope may lie in Adocia’s ultra-rapid insulin, which faster action, combined with better algorithms, could significantly improve daily diabetes
Gérard Soula, Adocia CEO
On World Diabetes Day, BFM TV highlighted “the everyday life” of a person with type 1 diabetes (PWD). Taking insulin at mealtime, or even after, is crucial for PWD because it allows marked improvement in the accuracy of the insulin dosage and the person’s quality of life. Gérard Soula, CEO of Adocia, explains how BioChaperone
This October 14th, Gérard Soula, Adocia CEO was interviewed following the Press Release: Adocia obtains additional financial resources to accelerate its growth. To watch the video produced by Didier Testot on the French Web TV: www.labourseetlavie.com
At the occasion of World Diabetes Day, Thursday November 14th, 2019 Adocia comes to meet you to make you discover its promising portfolio and answer your questions. Biotech Agora’s mission is to introduce investors to highly innovative companies in the field of Life Sciences, such as Adocia. Adocia’s Executive team will welcome you on November 14
A success for the second Edition of the French Forum Lyon Pôle Bourse which was held last September 25th, 2019 in Lyon! This Forum focuses on one to one meetings between investors and regional companies. During this event, 84 professional investors met the 36 listed companies. To watch the video about Adocia by Olivier Soula, Deputy
Dear investors, Meet Adocia at the second Forum “Lyon Pole Bourse” which will held in Lyon next September 25th! This Forum is focusing on “one to one” meetings between investors and regional companies. To register: www.forum-lyon-pole-bourse.com
Adocia announces an oral presentation at the 55th European Association for the Study of Diabetes EASD congress, being held September 16-20, 2019 in Barcelona, Spain. This Abstract will cover its ADO09 (pramlintide insulin) product: Oral Presentation #109: ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus
To listen to the Adocia conference call which was held on Friday August 23rd, following  the Press Release of the Arbitration decision, please, click on the link: ADOC UPDATE – English: https://edge.media-server.com/mmc/p/zqatu6o4 ADOC UPDATE – French: https://edge.media-server.com/mmc/p/k85cjxre  
Dear all, Following Adocia’s Press Release distributed today regarding the decision in the Second Phase of the Arbitration with Eli Lilly, Adocia will hold a conference call to answer shareholders’ questions today, August 23rd, 2019. The following members of Adocia’s leadership team will conduct the call: Gérard Soula, President and CEO Olivier Soula, R&D Director
Last June 9th and 10th, Adocia presented two abstracts during the 79th Scientific Sessions organized by the American Diabetes Association® this year at the Moscone Center in San Francisco (USA)   Oral  Presentation #150-OR: Biochaperone Pramlintide Insulin (BCPramIns), A New Co-formulation Of Pramlintide (pram) And Human Insulin (ins), Improves Post-prandial Blood Glucose (BG) Versus Both